bf/NASDAQ:AVXL_icon.jpeg

NASDAQ:AVXL

Anavex Life Sciences Corp.

  • Stock

9.31

−2%

−0.24

USD last updated 21/08 01:59:19

Last Close

9.55

21/08 20:57

Market Cap

391.04M

Beta: 0.75

Volume Today

740.90K

Avg: 1.09M

PE Ratio

−8.31

PFCF: −16.52

OverviewFinancialsAPI

This will be loaded shortly.

Loading

This is also still loading.

This will be loaded shortly.

Loading

This is also still loading.

This will be loaded shortly.

Loading

This is also still loading.

    Description

    Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II c...Show More

    Excel Tearsheet

    Earnings

    Earnings per Share (Estimate*)

    -0.2-0.15-0.1-0.052018-12-122020-09-292022-08-092024-04-082024-12-23

    Revenue (Estimate*)

    0.000.000.010.010.012018-12-122020-09-292022-08-092024-04-082024-12-23

    *Estimate based on analyst consensus